Stablepoint Partners LLC sells 86 shares of Danaher Co. (NYSE:DHR)

VaselineSeptember 6, 2024

0 4 minutes read

Stablepoint Partners LLC reduced its holdings in Danaher Co. (NYSE:DHR – Free Report) by 5.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,638 shares of the conglomerate’s stock after selling 86 shares during the period. Stablepoint Partners LLC’s holdings in Danaher were worth $445,000 at the end of the most recent reporting period.

A number of other hedge funds have recently bought and sold shares of the company. Gilbert & Cook Inc. boosted its holdings in Danaher by 4.9% in the 4th quarter. Gilbert & Cook Inc. now owns 1,830 shares of the conglomerate’s stock worth $423,000 after acquiring an additional 86 shares in the last quarter. Los Angeles Capital Management LLC boosted its holdings in shares of Danaher by 1.3% during the 4th quarter. Los Angeles Capital Management LLC now owns 3,470 shares of the conglomerate’s stock worth $803,000 after buying an additional 43 shares in the that period. Accretive Wealth Partners LLC raised its stake in Danaher by 12.9% in the fourth quarter. Accretive Wealth Partners LLC now owns 3,632 shares of the conglomerate’s stock valued at $840,000 after buying an additional 414 shares in the last quarter. Wealthcare Advisory Partners LLC boosted its holdings in Danaher by 8.8% in the 4th quarter. Wealthcare Advisory Partners LLC now owns 1,649 shares of the conglomerate’s stock worth $382,000 after acquiring an additional 134 shares during the period. Finally, Gryphon Financial Partners LLC lifted its position in Danaher by 19.1% during the 4th quarter. Gryphon Financial Partners LLC now owns 2,917 shares of the conglomerate’s stock worth $675,000 after acquiring an additional 468 shares during the period. shares in the last quarter. 79.05% of shares are owned by institutional investors and hedge funds.

Changes in Analyst Ratings

A number of equities analysts have recently commented on DHR shares. Jefferies Financial Group assumed coverage on Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective on the stock. Evercore ISI decreased their price target on Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Goldman Sachs Group upped their price objective on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Finally, Bank of America boosted their target price on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $278.94.

Want more great investment ideas?

Read our latest Danaher review

Indoor activity

In related news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available on the SEC’s website. In other news, CFO Matthew Mcgrew sold 16,172 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the transaction, the chief financial officer now directly owns 29,407 shares in the company, valued at $8,229,254.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available on the SEC’s website. Also, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 39,659 shares of company stock worth $11,042,433. Insiders own 11.10% of the company’s shares.

Danaher stock performance

Shares of NYSE:DHR opened at $264.80 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43, and a quick ratio of 1.04. The company’s fifty day moving average price is $260.98 and its two hundred day moving average price is $255.61. Danaher Co. it has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The stock has a market cap of $196.13 billion, a price-to-earnings ratio of 44.88, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83.

Danaher (NYSE:DHR – Get Your Free Report ) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.15. The company had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company’s quarterly revenue was down 2.9% compared to the same quarter last year. In the same quarter last year, the firm earned $2.05 EPS. As a group, analysts predict that Danaher Co. will post 7.59 EPS for the current fiscal year.

About Danaher

(Free report)

Danaher Corporation designs, manufactures and markets professional, medical, industrial and commercial products and services worldwide. The Biotechnology segments provide bioprocess technologies, consumables and services that advance, accelerate and integrate drug development and manufacturing; cell line and cell culture media development services; cell culture media, process fluids and manufacturing buffers, chromatography resins, filtration technologies, aseptic fill finishing; disposable hardware and supplies and services such as design and installation of complete manufacturing suites; laboratory filtration, separation and purification; laboratory-scale protein purification and analytical tools; reagents, membranes and services; and filtration solutions for health care.